Earnings Call · Q4 FY2023·2024-02-29

Q4 23EPS -13.33%·Rev n/aQ3 23EPS +21.43%·Rev n/aQ2 23EPS +42.86%·Rev n/aQ1 23EPS +100.00%*·Rev n/a⚠ consensus missing

PUMA BIOTECHNOLOGY, INC. PBYI

Mariann Ohanesian — Investor Relations or Communications

Alan Auerbach — Chief Executive Officer, President and Chairman of the Board

Jeff Ludwig — Commercial Executive

Maximo Nougues — Chief Financial Officer

−5.3%1d on move date−6.2% vs SPY3d−16.7%5d−7.6%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more PBYI calls or request research access.

More PBYI calls Browse calls Request research access